AVBP Stock Analysis: ArriVent BioPharma, Common | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.615m USD | 12M Return: 69.5% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 18.5M
Warnings
Tailwinds
Seasonality 2.4 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on developing oncology therapies for cancers with limited treatment options. Its lead candidate, firmonertinib, is an oral tyrosine kinase inhibitor being studied across multiple non-small cell lung cancer (NSCLC) settings driven by EGFR mutations, including a Phase 3 trial in EGFR exon 20 insertion NSCLC and Phase 1b trials in PACC and classical EGFR-mutated disease. The broader pipeline includes an antibody-drug conjugate (ARR-217) aimed at gastrointestinal cancers and additional early-stage solid tumor programs.
The company, founded in 2021 and headquartered in Newtown Square, Pennsylvania, relies on a partnership-driven model, collaborating with developers such as Shanghai Allist Pharmaceuticals, Beijing InnoCare Pharma Tech, Jiangsu Alphamab Biopharmaceuticals, Lepu Biopharma, and Aarvik Therapeutics to access and advance its candidates. As a clinical-stage biotech, ArriVent has no approved products and depends on capital markets and collaboration milestones rather than product sales to fund operations, a typical structure for small-cap oncology developers that went public in early 2024.
- Firmonertinib Phase 3 NSCLC trial data readout
- FDA approval pathway for exon 20 insertion indication
- Cash burn and capital raises pressure clinical-stage valuation
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.38 > 0.02 and ΔFCF/TA 17.00 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.38 > 3% & CFO -134.5m > Net Income -145.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 13.95 > 1.5 & < 3 |
| Outstanding Shares: last quarter (45.1m) vs 12m ago 32.95% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.93 (Total Current Assets 348.7m - Total Current Liabilities 25.0m) / Total Assets 349.3m |
| B: -1.28 (Retained Earnings -448.0m / Total Assets 349.3m) |
| C: -0.56 (EBIT TTM -156.9m / Avg Total Assets 282.4m) |
| D: 12.80 (Book Value of Equity 324.0m / Total Liabilities 25.3m) |
| Altman-Z'' = 11.60 = AAA |
As of July 08, 2026, the stock is trading at USD 34.18 with a total of 402,215 shares traded. Over the past week, the price has changed by -0.55%, over one month by +12.07%, over three months by +35.69% and over the past year by +69.46%.
Current recommended Stop Loss: 30.90 (which is 9.6% or 1.9 ATR below the current price).
ArriVent BioPharma, Common has received a consensus analysts rating of 4.86. Therefore, it is recommended to buy AVBP.
- StrongBuy: 6
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 43.6 | 27.7% |
P/B = 4.9597
Revenue TTM = 0.0 USD
EBIT TTM = -156.9m USD
EBITDA TTM = -156.9m USD
Long Term Debt = 320k USD (estimated: total debt 419k - short term 99.0k)
Short Term Debt = 99.0k USD (from shortTermDebt, last quarter)
Debt = 419k USD (from shortLongTermDebtTotal, last quarter) (leases 419k already included)
Net Debt = -326.0m USD (calculated: Debt 419k - CCE 326.4m)
Enterprise Value = 1.29b USD (1.61b + Debt 419k - CCE 326.4m)
Interest Coverage Ratio = unknown (Ebit TTM -156.9m / Interest Expense TTM 0.0)
EV/FCF = -9.58x (Enterprise Value 1.29b / FCF TTM -134.5m)
FCF Yield = -10.43% (FCF TTM -134.5m / Enterprise Value 1.29b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 3.69 (Enterprise Value 1.29b / Total Assets 349.3m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 419k)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -123.9m (EBIT -156.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 13.95 (Total Current Assets 348.7m / Total Current Liabilities 25.0m)
Debt / Equity = 0.00 (Debt 419k / totalStockholderEquity, last quarter 324.0m)
Debt / EBITDA = 2.08 (negative EBITDA) (Net Debt -326.0m / EBITDA -156.9m)
Debt / FCF = 2.42 (negative FCF - burning cash) (Net Debt -326.0m / FCF TTM -134.5m)
Total Stockholder Equity = 296.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -51.43% (Net Income -145.2m / Total Assets 349.3m)
RoE = -48.98% (Net Income TTM -145.2m / Total Stockholder Equity 296.5m)
RoCE = -52.85% (EBIT -156.9m / Capital Employed (Equity 296.5m + L.T.Debt 320k))
RoIC = -38.20% (negative operating profit) (NOPAT -123.9m / Invested Capital 324.4m)
WACC = 8.51% (E(1.61b)/V(1.62b) * Re(8.51%) + D(419k)/V(1.62b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 8.51% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 93.21 | Cagr: 14.10%
[DCF] Fair Price = unknown (Cash Flow -134.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.13 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.98 | Chg30d=-0.31% | Revisions=-57% | Analysts=9
EPS next Quarter (2026-09-30): EPS=-0.97 | Chg30d=+3.07% | Revisions=+25% | Analysts=9
EPS current Year (2026-12-31): EPS=-4.02 | Chg30d=-0.47% | Revisions=-42% | GrowthEPS=+6.9% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-3.50 | Chg30d=-3.86% | Revisions=-36% | GrowthEPS=+13.0% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -48% (up=5, down=17)